CJC-1295

peptideresearch peptide

Research chemical — not an approved drug or dietary supplement

This compound is sold for research and is not FDA-approved for human use or as a dietary supplement. Human evidence is limited; purity and dosing of consumer products are unverified. The data below is an evidence review for education only — talk to a clinician before considering it.

At a glance

Best for
Not established — investigational
Main caution
Unapproved long-acting GHRH analog with sustained GH elevation of unknown long-term risk and unregulated purity
Evidence strength: Limited early human/preclinical data; no approved human use

What is it

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) designed to stimulate the pituitary to release growth hormone; the 'DAC' (Drug Affinity Complex) version binds albumin to extend its half-life for sustained GH release. It is proposed to raise GH and IGF-1, and is often combined with a ghrelin-mimetic in research/non-clinical use. Human data are limited to small early-phase pharmacokinetic studies; it is not FDA-approved, has no established long-term safety profile, and is not a dietary supplement. It is sold only 'for research use only.'

Is it worth it for you?

Probably skip if…

  • You expect an approved therapy — it is not FDA-approved and is not a supplement
  • You would source it from 'research use only' vendors with no purity or sterility controls
  • You are not prepared for unknown long-term effects of chronically elevated GH/IGF-1
  • You are uncomfortable with self-injection risks such as infection and contamination
  • You compete in sport — GHRH analogs and secretagogues are prohibited under WADA rules

Safety

Common side effects

Reported in limited settings: injection-site reactions (redness/itching), flushing, headache, transient water retention

Serious risks

  • Unregulated purity, sterility, and dosing of research-grade product
  • Unknown long-term effects of sustained GH/IGF-1 elevation, including theoretical risks for insulin resistance and growth of existing tumors
  • Injection-related infection and contamination risk
  • No clinical monitoring of hormone or glucose levels

Who should avoid it

  • Anyone without direct medical supervision
  • Pregnancy and breastfeeding
  • People with cancer or a history of cancer
  • People with diabetes or impaired glucose tolerance (without supervision)
  • Competitive athletes subject to anti-doping rules

Pregnancy & breastfeeding

Avoid — no safety data.

Choosing a product

Be skeptical of

  • 'Proven' anti-aging, muscle-building, or fat-loss claims in humans
  • Vendors selling 'for research use only' product for human injection
  • Implying it is a safe or approved substitute for prescription growth hormone

Track CJC-1295 with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.

Coming to App Store
Evidence-based·Last reviewed May 30, 2026·Evidence current as of May 30, 2026·How we grade evidence

Disclaimer: This compound is not approved by the FDA for human use and is not a dietary supplement. This page is an educational review of available research — much of it preclinical or early-stage — not a recommendation to use it. Consumer product quality is unregulated. Consult a qualified clinician.